Northwest Biotherapeutics (NWBO) Debt to Equity (2016 - 2025)
Northwest Biotherapeutics (NWBO) has 16 years of Debt to Equity data on record, last reported at -$0.16 in Q3 2025.
- For Q3 2025, Debt to Equity rose 58.42% year-over-year to -$0.16; the TTM value through Sep 2025 reached -$0.16, up 58.42%, while the annual FY2024 figure was -$0.23, 48.15% up from the prior year.
- Debt to Equity reached -$0.16 in Q3 2025 per NWBO's latest filing, up from -$0.18 in the prior quarter.
- Across five years, Debt to Equity topped out at -$0.08 in Q1 2025 and bottomed at -$1.06 in Q4 2021.
- Average Debt to Equity over 5 years is -$0.47, with a median of -$0.37 recorded in 2024.
- Peak YoY movement for Debt to Equity: tumbled 2201.37% in 2021, then soared 80.0% in 2022.
- A 5-year view of Debt to Equity shows it stood at -$1.06 in 2021, then skyrocketed by 36.51% to -$0.68 in 2022, then skyrocketed by 33.62% to -$0.45 in 2023, then soared by 48.15% to -$0.23 in 2024, then surged by 33.3% to -$0.16 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were -$0.16 in Q3 2025, -$0.18 in Q2 2025, and -$0.08 in Q1 2025.